Alzheimer's News Today Home | Alzheimer's News Today
网页Fosgonimeton fails to meet goal in Alzheimer’s clinical trial: Data. Fosgonimeton, an investigational medication from Athira Pharma, failed to significantly improve cognitive and daily functioning in adults with mild to moderate Alzheimer’s disease who took part in a Phase 2/3 clinical trial, despite being safe and well tolerated, top-line data show.
ALZ-801 for 2 years seen to sustain cognition in early Alzheimer’s
网页2023年9月22日 · These are the top-line findings of an ongoing Phase 2 clinical trial (NCT04693520), whose two-year data also showed that Alzheon’s experimental therapy preserved the hippocampus, a brain structure important for memory that is damaged first in Alzheimer’s.. Importantly, ALZ-801’s safety profile over two years continued to show no increased risk of brain swelling and bleeds, which have ...
Medicare now will cover costs of amyloid PET scan in Alzheimer's
网页2023年10月20日 · An amyloid PET scan typically is more sensitive than other imaging scans, and thus may be a better tool for making a diagnosis. However, such tests are expensive: Without insurance, amyloid PET scans can cost an average of $3,000 per test or more. People on Medicare generally pay 20% of the costs of imaging scans after meeting their deductible.
Lecanemab Slows Dementia of Early Alzheimer’s in Phase 3 Trial
网页2022年10月4日 · The trial also met key secondary goals, with lecanemab outperforming placebo at reducing plaque levels and on other measures of disease severity, namely the Alzheimer’s Disease Assessment Scale-cognitive subscale14 (ADAS-cog14), Alzheimer’s Disease Composite Score (ADCOMS) and the Alzheimer’s Disease Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS ...
Oral ALZ-801 Found to Improve Memory in Alzheimer’s Patients
网页2022年8月1日 · Treatment with Alzheon ‘s oral candidate ALZ-801 (valiltramiprosate) lowered levels of a key biomarker for Alzheimer’s disease — and led to significant memory improvements in people with the neurodegenerative disorder.. That’s according to data from a six-month interim analysis of an ongoing Phase 2 biomarker trial (NCT04693520) evaluating the potential therapy.
News Archives - Alzheimer's News Today
网页Zunveyl, therapy that may be easier on GI system, wins FDA approval. The U.S. Food and Drug Administration (FDA) has approved the oral therapy Zunveyl (benzgalantamine), previously known as ALPHA-1062, to treat mild-to-moderate Alzheimer’s disease. “The approval of Zunveyl is a pivotal moment in the fight against Alzheimer’s disease as it ...
Full Phase 3 Trial Data Support Lecanemab for Early Alzheimer’s
网页2022年12月6日 · About 1.5 years of treatment with lecanemab (BAN2401) — now under regulatory review in the U.S. — was found to significantly slow the progression of dementia symptoms in people with early-onset Alzheimer’s disease.
FDA approves Rexulti for agitation tied to Alzheimer’s dementia
网页2023年5月11日 · Otsuka and Lundbeck’s supplemental new drug application seeking the approval of Rexulti for agitation associated with Alzheimer’s dementia was granted priority review by the FDA — a designation given to shorten the typical review time of therapies that have the potential to substantially improve care for serious conditions. Under priority review, the FDA issues its decision in six months ...
Neurostimulation Device for Alzheimers Granted FDA …
网页2021年1月25日 · Non-invasive Neurostimulation Device Wins FDA’s Breakthrough Status. by Patricia Inacio, PhD January 25, 2021. Cognito Therapeutic ’s neurostimulation device — a next-generation digital therapeutic designed to treat memory and cognition symptoms in Alzheimer’s disease — has been granted a breakthrough device designation by the U.S ...
Phase 3 Trial of Diabetes Treatment in Early Alzheimer’s Patients...
网页2021年1月4日 · The Phase 3a trial will enroll about 3,700 people in the early stages if Alzheimer’s disease, and will evaluate the efficacy and safety of 14 mg of oral semaglutide, compared with a placebo, taken once daily. The study is anticipated to run for about two years. “Alzheimer’s disease has been an area of extensive research in the past ...